Free Trial
NASDAQ:TBPH

Theravance Biopharma (TBPH) Stock Price, News & Analysis

Theravance Biopharma logo
$14.07 +0.19 (+1.37%)
Closing price 04:00 PM Eastern
Extended Trading
$14.06 -0.01 (-0.04%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Theravance Biopharma Stock (NASDAQ:TBPH)

Advanced

Key Stats

Today's Range
$13.65
$14.25
50-Day Range
$10.90
$14.47
52-Week Range
$7.88
$14.55
Volume
377,753 shs
Average Volume
489,611 shs
Market Capitalization
$708.57 million
P/E Ratio
58.63
Dividend Yield
N/A
Price Target
$23.00
Consensus Rating
Buy

Company Overview

Theravance Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

TBPH MarketRank™: 

Theravance Biopharma scored higher than 65% of companies evaluated by MarketBeat, and ranked 327th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Theravance Biopharma has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    Theravance Biopharma has a consensus price target of $23.00, representing about 63.5% upside from its current price of $14.07.

  • Amount of Analyst Coverage

    Theravance Biopharma has only been the subject of 3 research reports in the past 90 days.

  • Read more about Theravance Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Theravance Biopharma are expected to grow in the coming year, from ($1.09) to $0.35 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Theravance Biopharma is 58.63, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 284.57.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Theravance Biopharma is 58.63, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 267.46.

  • Price to Book Value per Share Ratio

    Theravance Biopharma has a P/B Ratio of 3.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Theravance Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    9.63% of the float of Theravance Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Theravance Biopharma has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Theravance Biopharma has recently increased by 25.28%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Theravance Biopharma does not currently pay a dividend.

  • Dividend Growth

    Theravance Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.63% of the float of Theravance Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Theravance Biopharma has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Theravance Biopharma has recently increased by 25.28%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Theravance Biopharma has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Theravance Biopharma this week, compared to 3 articles on an average week.
  • Search Interest

    3 people have searched for TBPH on MarketBeat in the last 30 days.
  • MarketBeat Follows

    2 people have added Theravance Biopharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Theravance Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $227,800.00 in company stock.

  • Percentage Held by Insiders

    Only 6.90% of the stock of Theravance Biopharma is held by insiders.

  • Percentage Held by Institutions

    99.10% of the stock of Theravance Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Theravance Biopharma's insider trading history.
Receive TBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TBPH Stock News Headlines

Theravance Biopharma, Inc. (NASDAQ:TBPH) Short Interest Up 25.3% in August
Claim Your Share of $5.39 BILLION in AI Equity Checks
The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enforcing that means a $5.39 billion pot must be paid out to everyday Americans. See, virtually every AI model is built off stolen data...tc pixel
B. Riley Begins Coverage on Theravance Biopharma (NASDAQ:TBPH)
See More Headlines

TBPH Stock Analysis - Frequently Asked Questions

Theravance Biopharma's stock was trading at $9.41 at the beginning of 2025. Since then, TBPH shares have increased by 49.5% and is now trading at $14.07.

Theravance Biopharma, Inc. (NASDAQ:TBPH) posted its earnings results on Thursday, May, 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.16. The biopharmaceutical company earned $15.39 million during the quarter, compared to analysts' expectations of $28.08 million. Theravance Biopharma had a net margin of 16.88% and a trailing twelve-month return on equity of 6.93%.
Read the conference call transcript
.

Theravance Biopharma's top institutional investors include Geode Capital Management LLC (1.79%), Bank of America Corp DE (1.08%), Camber Capital Management LP (0.90%) and BNP Paribas Financial Markets (0.77%). Insiders that own company stock include Richard A Graham and Rhonda Farnum.
View institutional ownership trends
.

Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Theravance Biopharma investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/08/2025
Today
9/22/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TBPH
Previous Symbol
NASDAQ:TBPHV
CIK
1583107
Fax
N/A
Employees
110
Year Founded
1996

Price Target and Rating

High Price Target
$28.00
Low Price Target
$15.00
Potential Upside/Downside
+63.5%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.24
Trailing P/E Ratio
58.63
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$56.42 million
Net Margins
16.88%
Pretax Margin
51.91%
Return on Equity
6.93%
Return on Assets
3.52%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.70
Quick Ratio
6.70

Sales & Book Value

Annual Sales
$64.38 million
Price / Sales
11.01
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.57 per share
Price / Book
3.94

Miscellaneous

Outstanding Shares
50,360,000
Free Float
46,886,000
Market Cap
$708.57 million
Optionable
Optionable
Beta
0.04

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:TBPH) was last updated on 9/22/2025 by MarketBeat.com Staff
From Our Partners